🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

18 results for “tarlatamab” Clear

  1. ELECTROLYTES , DURVALUMAB, VASOPRESSIN (ARGIPRESSIN) , PREDNISOLONE , INFLIXIMAB, MYCOPHENOLATE MOFETIL, PARACETAMOL , Tarlatamab, Tarlatamab, TOCILIZUMAB, ETOPOSIDE, DEXAMETHASONE, SILTUXIMAB, CARBOPLATIN, CISPLATIN

    Amgen

    Extensive stage small cell lung cancer (ES-SCLC)

    phase 3 small molecule active

    1 trial

  2. MYCOPHENOLATE MOFETIL, ETOPOSIDE, DURVALUMAB, INFLIXIMAB, SILTUXIMAB, Tarlatamab, CARBOPLATIN, Tarlatamab

    Amgen

    Extensive stage small cell lung cancer (ES-SCLC). Small-cell lung cancer, accounting for 10% to 15% of lung cancer (Rudin et al, 2015), is an aggressive lung cancer subtype with neuroendocrine differentiation and strongly associated with smoking (Koinis et al, 2016). It displays a distinct natural history characterized by a high growth fraction, rapid doubling time and early establishment of widespread metastatic lesions (Gustafsson et al, 2008). Around 70% of patients are diagnosed with ES-SCLC, presenting with distant metastasis or tumor or nodal volume that is too large to be encompassed in a tolerable radiation plan.

    phase 3 small molecule active

    1 trial

  3. TOCILIZUMAB, Tarlatamab, DEXAMETHASONE, Placebo for Tarlatamab (AMG-757), PARACETAMOL , ELECTROLYTES , PREDNISOLONE , Tarlatamab, VASOPRESSIN (ARGIPRESSIN) , SILTUXIMAB

    Amgen

    Limited-Stage Small-Cell Lung Cancer (LS SCLC)

    phase 3 small molecule active

    1 trial

  4. Tarlatamab

    Amgen

    Extensive-Stage Small-Cell Lung Cancer

    phase 3 small molecule active

    1 trial

  5. Tarlatamab

    Amgen

    Small Cell Lung Cancer (SCLC)

    phase 3 small molecule active

    1 trial

  6. Tarlatamab, OXALIPLATINE VIATRIS 5 mg/ml, poudre pour solution pour perfusion, Dacarbazine "Lipomed", Tecentriq 1 200 mg concentrate for solution for infusion, Docetaxel Accord 80 mg/4 ml concentrate for solution for infusion, Temozolomide 100 mg hard capsules, OPDIVO 10 mg/mL concentrate for solution for infusion., KEYTRUDA 25 mg/mL concentrate for solution for infusion, Topotecan Accord Healthcare 4mg Powder for Concentrate for Solution for Infusion, IRINOTECAN VIATRIS 20 mg/ml, solution à diluer pour per

    CERO THERAPEUTICS HOLDINGS, INC.

    Advanced pulmonary or gastroenteropancreatic poorly differentiated neuroendocrine carcinomas (NECs)

    phase 3 small molecule active

    1 trial

  7. SILTUXIMAB, Tarlatamab, Tarlatamab

    Amgen

    Small Cell Lung Cancer (SCLC)

    phase 2 small molecule active

    1 trial

  8. Tarlatamab

    Amgen

    Relapsed/Refractory Small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  9. Tarlatamab, TARLATAMAB, Tarlatamab, SILTUXIMAB

    Amgen

    Relapsed/Refractory Small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  10. Tarlatamab, Tarlatamab

    Partner Therapeutics Limited

    Patients with pretreated extensive-stage small cell lung cancer (ES-SCLC) and ECOG PS 2

    phase 2 small molecule active

    1 trial

  11. Tarlatamab, Tarlatamab

    The George Institute

    Metastaic small cell lung cancer (SCLC) and other poorly differentitated neuroendocrine carcinomas (NECs)

    phase 2 small molecule active

    1 trial

  12. A Phase 1 Study Evaluating the Safety, Tolerability, and Pharmacokinetics of Tarlatamab in Subjects With Small Cell Lung Cancer (DeLLphi-300)

    Amgen

    Small Cell Lung Cancer

    phase 1 other active

    1 trial

  13. First-line Tarlatamab in Combination With Carboplatin, Etoposide, and PD-L1 Inhibitor in Subjects with Extensive Stage Small Cell Lung Cancer (ES SCLC) (DeLLphi-303)

    Amgen

    Extensive Stage Small cell lung cancer (ES-SCLC)

    phase 1 other active

    1 trial

  14. Phase 1b Study of Tarlatamab + ZL-1310 +/- Anti-PD-L1 in Small Cell Lung Cancer

    Amgen

    Small Cell Lung Cancer

    phase 1 other active

    1 trial

  15. Phase 1b Study of Tarlatamab in Combination with YL201 with or without Anti-PD-L1 in Subjects with Extensive Stage Small Cell Lung Cancer (DeLLphi-310)

    Amgen

    Extensive Stage Small Cell Lung Cancer (ES-SCLC)

    phase 1 other active

    1 trial

  16. Subcutaneous Tarlatamab in Subjects with Extensive Stage Small Cell Lung Cancer (DeLLphi-308)

    Amgen

    Extensive Stage Small Cell Lung Cancer (DeLLphi-308)

    phase 1 other active

    1 trial

  17. Tarlatamab

    Amgen

    Neuroendocrine Prostate Cancer

    phase 1 small molecule completed

    1 trial

  18. Tarlatamab

    BEONE MEDICINES AUS PTY LTD

    Extensive Stage Small Cell Lung Cancer

    phase 1 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources